StageZero Life Sciences Ltd.
SZLS.TO
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 09/30/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -35.21% | -35.21% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -35.21% | -35.21% |
| Cost of Revenue | -- | -- | -- | -43.14% | -40.71% |
| Gross Profit | -- | -- | -- | 249.72% | 162.35% |
| SG&A Expenses | -- | -- | -- | -41.97% | -43.27% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -- | -- | -45.42% | -45.42% |
| Operating Income | -- | -- | -- | 50.54% | 50.54% |
| Income Before Tax | -- | -- | -- | -197.51% | -197.51% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -- | -- | -- | -197.51% | -197.51% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | -- | -197.51% | -197.51% |
| EBIT | -- | -- | -- | 50.54% | 50.54% |
| EBITDA | -- | -- | -- | 50.82% | 50.82% |
| EPS Basic | -- | -- | -- | 2.54% | 1.80% |
| Normalized Basic EPS | -- | -- | -- | 68.22% | 67.61% |
| EPS Diluted | -- | -- | -- | 2.54% | 1.80% |
| Normalized Diluted EPS | -- | -- | -- | 68.22% | 67.61% |
| Average Basic Shares Outstanding | -- | -- | -- | 55.33% | 50.80% |
| Average Diluted Shares Outstanding | -- | -- | -- | 55.33% | 50.80% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
